Routine monitoring can help you get the most out of your treatment.
Measuring prostate-specific antigen (PSA) levels and imaging are 2 ways your doctor may watch for changes in your prostate cancer.
In fact, PSA testing and imaging have led to early detection of disease spread (metastasis) and the opportunity for improved outcomes.
If you have prostate cancer that has not yet spread to other parts of your body, but is no longer responding to hormone therapy, or if you have prostate cancer that has spread but is still responding to hormone therapy, ask your doctor about regular monitoring and advanced imaging to identify disease progression.
Prostate-specific antigen (PSA) is a normal protein made by the prostate. In healthy men, some PSA is found in the blood. If PSA levels in the blood are higher than normal, that can be a sign that something is wrong in the prostate. Routine testing of PSA levels helps your doctor know when to order imaging to check for disease progression.
For patients receiving hormone therapy for advanced prostate cancer, the National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education, dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives, recommends regular monitoring of PSA levels.
If PSA levels increase, imaging may be ordered to determine if prostate cancer has spread (metastasized).
Once your prostate cancer has spread (metastasized), you may benefit from PROVENGE. However, PSA is not a measurement of treatment success or survival outcomes. In the PROVENGE clinical trials, the main goal was not to lower PSA levels—it was to extend life. PROVENGE helped certain men with advanced prostate cancer (men with mCRPC who did not take prescription pain medicine for cancer-related pain) live longer, even when their PSA levels did not decrease. If you have any concerns about your PSA levels, you should share them with your urologist or oncologist.
When prostate cancer spreads, or becomes metastatic, it usually moves into the bones. The most common area for metastases is the spine. Imaging of the chest, abdomen, and pelvis provides important information about the spread of prostate cancer. Imaging may include:
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education, dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives, recommends regular imaging for advanced prostate cancer patients.
Along with increasing PSA levels, imaging can help your doctor identify disease spread early, to evaluate if you are a candidate for PROVENGE as the first treatment for metastatic castrate-resistant prostate cancer (mCRPC).
You might be thinking about how you can live a healthier lifestyle. It is important to talk with your healthcare team about any concerns you have about your health, including nutrition, exercise, and your emotions. Below are some questions you may consider asking your healthcare team.
Talk to your urologist or oncologist and find a treatment center.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.3.2018. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed June 21, 2018. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Activate your own immune system to seek out and attack your advanced prostate cancer with PROVENGE.
PROVENGE® (sipuleucel-T) is a prescription medicine that is used to treat certain patients with advanced prostate cancer. PROVENGE is made from your own immune cells.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Click here for full Prescribing Information.
Access this brochure to learn about PROVENGE and how it may help certain men with advanced prostate cancer (mCRPC) live longer.